Guardant Health Inc (OQ:GH)

May 07, 2024 08:00 am ET
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies in the industry.
Apr 03, 2024 08:05 am ET
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
Mar 13, 2024 05:00 pm ET
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer (CRC) in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine.
Mar 06, 2024 04:30 pm ET
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant date of February 26, 2024 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). Additi
Mar 01, 2024 05:30 am ET
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
Feb 22, 2024 04:05 pm ET
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
Feb 15, 2024 04:05 pm ET
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
Feb 01, 2024 04:05 pm ET
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jan 17, 2024 08:05 am ET
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco.
Jan 08, 2024 09:00 am ET
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023.
Jan 08, 2024 02:30 am ET
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA).
Jan 08, 2024 01:30 am ET
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA).
Jan 02, 2024 11:00 am ET
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company’s chief people officer, effective immediately.
Dec 21, 2023 09:00 am ET
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share.
Dec 20, 2023 04:05 pm ET
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
Dec 19, 2023 04:05 pm ET
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024. The date and details of the meeting are subject to confirmation by the FDA and publication in the Federal Register.
Dec 04, 2023 05:00 am ET
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.
Nov 30, 2023 08:05 am ET
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas. Highlights of the eight poster presentations include the use of blood-based testing to identify actionable biomarkers and predict therapy response in advanced breast cancer, and to detect residual disease and predict recurrence in patients with early-stage breast cancer.
Nov 15, 2023 04:05 pm ET
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units (“RSUs”) representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 15, 2023 03:00 am ET
Guardant Health to Appeal Federal District Court Verdict
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington.
Nov 12, 2023 06:00 pm ET
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
Nov 06, 2023 04:05 pm ET
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023.
Nov 03, 2023 08:00 am ET
Guardant Health to Participate in Upcoming November Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences:
Oct 31, 2023 08:05 am ET
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between research and care, today announced an initiative to integrate Guardant’s comprehensive genomic profiling tests within Flatir
Oct 23, 2023 03:45 am ET
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer. Results from the trial, which is an ISS study sponsored by IFOM ETS – the AIRC Institute of Molecular Oncology in Milan, Italy, and supported by Guardant Health, were presented today by study investigators at the ESMO Congre
Oct 16, 2023 04:05 pm ET
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Sep 06, 2023 08:05 am ET
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.
Sep 05, 2023 08:05 am ET
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU® (trastuzumab deruxtecan). ENHERTU is a specifically engineered HER2-directed antibody drug conjugate developed by Daiichi Sankyo.
Sep 01, 2023 03:46 pm ET
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.
Aug 31, 2023 04:05 pm ET
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York.
Aug 17, 2023 04:05 pm ET
Guardant Health to Host Investor Day on September 7, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY starting at 8:00 a.m. Eastern time / 5:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team.
Aug 03, 2023 04:05 pm ET
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023.
Aug 01, 2023 04:05 pm ET
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership.
Jul 20, 2023 08:05 am ET
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It was the first blood-only liquid biopsy test commercially available for MRD testing.
Jul 12, 2023 04:05 pm ET
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jul 05, 2023 08:05 am ET
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), effective July 24, 2023, for its Guardant360® CDx liquid biopsy test for comprehensive genomic profiling (CGP) for patients with advanced or metastatic solid tumor cancers. This announcement follows the regulatory approval of the Guardant360 CDx test by the MHLW in March 2022.
May 31, 2023 08:05 am ET
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.
May 29, 2023 09:00 pm ET
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers  The liquid biopsy test is also approved as a companion diagnostic for TAGRISSO® (osimertinib) in non-small cell lung cancer  This is the first blood test to be approved by Singapore's Health Sciences Authority for comprehensive genomic profiling for all solid tumors  SINGAPORE, May 29, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) announced today that Singapore's Health Sciences Authority (HSA)
May 26, 2023 08:00 am ET
Guardant Health to Participate in Upcoming June Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
May 22, 2023 10:03 pm ET
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions an
May 22, 2023 04:23 pm ET
Guardant Health Announces Proposed Public Offering of Common Stock
Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant Health. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the propose
May 17, 2023 08:05 am ET
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the Guardant360 liquid biopsy test from Anthem Blue Cross and Blue Shield, Aetna and Humana. With this additional coverage, Guardant360 CDx/Guardant360 is now covered for comprehensive genomic profiling by all major U.S. commercial health insurers.
May 16, 2023 08:00 am ET
Guardant Health Releases Inaugural ESG Report
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy.
May 09, 2023 04:05 pm ET
Guardant Health Reports First Quarter 2023 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023.
May 09, 2023 10:15 am ET
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC).
May 08, 2023 04:05 pm ET
Guardant Health Announces Additions to Leadership Team
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer.
May 05, 2023 08:00 am ET
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m. PT.
Apr 27, 2023 04:05 pm ET
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada.
Apr 25, 2023 08:05 am ET
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.
Apr 21, 2023 08:05 am ET
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023.
Apr 19, 2023 04:05 pm ET
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Apr 18, 2023 08:05 am ET
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant360 Response test. Guardant360 Response is the first blood-only test that enables doctors to track molecular response through changes in circulating tumor DNA (ctDNA) levels, to get an early indication of metastatic or advanced cancer patient response to immune checkpoint inhibitor therapy.
Apr 11, 2023 08:05 am ET
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2023 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida.
Mar 21, 2023 08:05 am ET
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-
Mar 10, 2023 08:05 am ET
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC).
Feb 27, 2023 04:05 pm ET
Musa Tariq Joins Guardant Health Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.
Feb 23, 2023 04:05 pm ET
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022.
Feb 17, 2023 08:00 am ET
Guardant Health to Participate in Upcoming March Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Feb 15, 2023 08:05 am ET
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the initiation of a new study to examine patient preference for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC), and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity – University of Chicago Medicine (CAHE-UCM).
Feb 08, 2023 08:05 am ET
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced or metastatic breast or non-small cell lung cancer (NSCLC).
Feb 02, 2023 08:05 am ET
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positi
Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today a strategic collaboration on the development, regulatory approval and commercialization of the Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for taletrectinib in the United States and European Union. Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1
Feb 02, 2023 06:00 am ET
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be dismissed:
Feb 01, 2023 04:05 pm ET
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jan 31, 2023 08:05 am ET
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s portfolio of cancer tests and to power the next generation of biomarker and drug discovery.
Jan 30, 2023 07:05 am ET
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic brea
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant), a nonsteroidal selective estrogen receptor degrader to be commercialized by Stemline Therapeutics, Inc., a wholly-owned subsidiary of Menarini Group.
Jan 19, 2023 08:05 am ET
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trust on Part C of its “Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer” (TRACC) study, which will evaluate the use of circulating tumor DNA (ctDNA) to guide chemotherapy treatment decisions after curative-intent surgery in patients with early-stage colorectal cancer (CRC). The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the
Jan 17, 2023 04:05 pm ET
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.
Jan 09, 2023 08:05 am ET
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced preliminary, unaudited results for the year ended December 31, 2022.
Dec 28, 2022 08:00 am ET
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
Dec 21, 2022 08:05 am ET
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.
Dec 15, 2022 04:16 pm ET
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer (CRC) in average-risk adults.
Dec 08, 2022 04:05 pm ET
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer. The initiative is part of a larger strategic collaboration investigating the use of liquid biopsy as a tool to inform early therapy intervention.
Dec 01, 2022 08:05 am ET
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas. The six poster presentations highlight the use of the Guardant360® blood test and the GuardantINFORM™ real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and monitor molecular response to therapy based on specific breast cancer driver mutations.
Nov 03, 2022 04:05 pm ET
Guardant Health Reports Third Quarter 2022 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022.
Oct 10, 2022 04:05 pm ET
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Sep 09, 2022 04:30 pm ET
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.
Sep 06, 2022 08:05 am ET
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, September 9-13 in Paris, France. Among the seven abstracts are an oral presentation and posters highlighting the use of Guardant Health’s blood tests and real-world evidence dataset to advance cancer therapy trials, predict and monitor patient response to therapy, and identify genomic mechanisms of acquired resistance to cancer therapy.
Aug 31, 2022 08:05 am ET
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence (RWE) platform to help accelerate development efforts for Merck KGaA, Darmstadt, Germany‘s precision oncology pipeline. The expanded strategic collaboration will focus on therapy development for core cancer indications with significant unmet need.
Aug 29, 2022 04:05 pm ET
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.
Aug 15, 2022 08:05 am ET
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Guardant Reveal™, the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer (CRC), is now available for patients with breast and lung cancers.
Aug 12, 2022 08:05 am ET
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic (CDx) to select patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations for treatment with ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate (ADC) jointly developed and commercialized by Daiichi Sankyo and AstraZen
Aug 08, 2022 04:05 pm ET
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.
Aug 08, 2022 06:15 am ET
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The
Aug 05, 2022 08:05 am ET
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360™ to help physicians inform treatment decisions, GuardantOMNI™ to advance cancer therapy trials, and GuardantINFORM™ for targeted drug develo
Aug 04, 2022 04:05 pm ET
Guardant Health Reports Second Quarter 2022 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2022.
Aug 02, 2022 08:05 am ET
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after surgery to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy. It is the first blood-only liquid biopsy test available for MRD testing in patients with c
Jul 13, 2022 04:05 pm ET
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jul 07, 2022 08:05 am ET
Steve E. Krognes Joins Guardant Health Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc.
Jun 13, 2022 08:05 am ET
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.
May 26, 2022 04:05 pm ET
Guardant Health to Participate in Upcoming June Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
May 25, 2022 03:01 am ET
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona.
May 23, 2022 08:05 am ET
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metastatic breast cancer therapy.
May 21, 2022 03:01 am ET
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC). These data were presented during an oral presentation at Digestive Disease Week 2022.
May 05, 2022 04:05 pm ET
Guardant Health Reports First Quarter 2022 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2022.
May 02, 2022 08:05 am ET
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC.
Apr 28, 2022 08:05 am ET
Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
Apr 13, 2022 04:05 pm ET
Guardant Health to Report First Quarter Financial Results on May 5, 2022
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Apr 11, 2022 03:30 pm ET
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the ability of the company’s investigational next-generation Guardant SHIELD™ multi-cancer assay to accurately detect early-stage cancers. This assay is designed to analyze approximately 20,000 epigenomic biomarkers that are informative for detection of a wide range of solid tumors in a single blood test. The data for four cancer types were demonstrated as examples: colorectal, lung, pancreatic and bladder. These cancers alone account for more than 200,000 cancer-related deaths in t
Apr 04, 2022 08:05 am ET
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive health record, to integrate the company’s broad portfolio of cancer tests with Epic. This integration will make it easier for health systems, community healthcare providers and retail health clinics to make Guardant Health blood tests part of routine clinical care by providing direct ordering access and results delivery.
Mar 17, 2022 08:05 am ET
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.
Mar 14, 2022 04:05 pm ET
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors.
Mar 09, 2022 08:05 am ET
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data from its broad portfolio of blood tests at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Included in the presentation will be data from its multi-cancer screening assay, next-generation Guardant SHIELD.
Mar 08, 2022 08:05 am ET
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext™ under the existing local coverage determination (LCD) (MolDX: Next-Generation Sequencing for Solid Tumors). Guardant360 TissueNext is the company’s first tissue-based test to help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment.
Feb 23, 2022 04:05 pm ET
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and year ended December 31, 2021.
Feb 07, 2022 04:05 pm ET
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating virtually in the following investor conferences.
Feb 01, 2022 04:05 pm ET
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jan 19, 2022 08:05 am ET
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022.
Jan 18, 2022 08:05 am ET
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80. The study is anticipated to run in approximately 100 centers in the United States and Europe.
Jan 07, 2022 05:15 pm ET
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
Guardant Health, Inc. (Nasdaq: GH) today announced that it has reached an agreement to settle all pending litigation concerning the company’s digital sequencing technology patents with Foundation Medicine, Inc. Pursuant to the settlement agreement, Foundation Medicine will pay Guardant Health $25 million as well as future royalties for the remaining term of the licensed digital sequencing technology patents. In turn, Guardant Health will grant Foundation Medicine a non-exclusive license to a defined subset of its digital sequencing technology patents. As a result of this settlement, all pendin
Dec 29, 2021 08:05 am ET
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Dec 17, 2021 08:05 am ET
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has reached its target enrollment of 12,750 patients in ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Encounter), a registrational study to evaluate the performance of its LUNAR™-2 blood test to detect colorectal cancer (CRC) in average-risk adults. Subject to positive study results, the number of patients currently enrolled in ECLIPSE is targeted to support a premarket ap
Dec 06, 2021 08:05 am ET
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio B
sGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present new data demonstrating the benefits of using the Guardant360® liquid biopsy test to help guide targeted therapy options for patients with advanced breast cancer at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-11. These studies were based on data from the GuardantINFORM™ real-world clinical genomic platform, which features extensive de-identified genomic data and aggregated commercial payer claims from advanced cancer patients who received the Gu
Nov 11, 2021 04:05 pm ET
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that a study published in Nature Medicine reinforces the benefits of using the Guardant360® liquid biopsy test to help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC). Led b
Nov 08, 2021 04:05 pm ET
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upcoming 2021 Stifel Healthcare Conference.
Nov 04, 2021 04:05 pm ET
Guardant Health Reports Third Quarter 2021 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2021.
Nov 03, 2021 08:05 pm ET
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and The Royal Marsden NHS Foundation Trust, one of the United Kingdom’s (UK) leading cancer research organizations, have agreed to enter into a partnership to establish an in-house liquid biopsy testing service using Guardant Health’s industry-leading proprietary digital sequencing platform.
Oct 25, 2021 08:05 am ET
Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), presents data at the American College of Gastroenterology Annual Scientific Meeting being held from October 22-27, showing its LUNAR-2 blood test, which has been developed to screen average-risk patients for colorectal cancer (CRC), offers optimized sensitivity and specificity in identifying those with early-stage CRC. This study was selected by the ACG Abstract Selection Committee as the recipient of the International Award.
Oct 20, 2021 04:30 pm ET
Guardant Health Appoints Myrtle Potter to Its Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors.
Oct 08, 2021 08:05 am ET
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Oct 05, 2021 08:05 am ET
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-patient prospective, observational, multi-center study designed to evaluate the performance of its Guardant Reveal™ liquid biopsy test to predict cancer recurrence after curative intent treatment, across 11 solid tumor types.
Oct 04, 2021 09:31 am ET
Thinking about trading options or stock in Guardant Health, Tesla, Arch Resources, AMC Entertainment, or American Airlines?
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GH, TSLA, ARCH, AMC, and AAL.
Sep 15, 2021 04:00 am ET
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.
Sep 07, 2021 08:05 am ET
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical decision-making in advanced lung...
Sep 02, 2021 04:05 pm ET
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference. Guardant Health’s management is scheduled to...
Aug 06, 2021 04:15 pm ET
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.
Aug 05, 2021 04:05 pm ET
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company’s strategic objectives for future growth. Under this structure, Helmy Eltoukhy, CEO, and AmirAli Talasaz, President, will serve as co-CEOs of Guardant Health. Both Eltoukhy and Talasaz will continue to serve on the Board of Directors and Eltoukhy will assume the role of Chairman. In addition, Meghan Joyce, Chief Operating Officer and Executive Vice President of Platform at Oscar Health, will join the Company’s Board as an Independent Director.
Aug 05, 2021 04:03 pm ET
Guardant Health Reports Second Quarter 2021 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2021.
Jul 20, 2021 08:10 am ET
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
Fight Colorectal Cancer (Fight CRC), the nation's leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back to routine colorectal cancer screening.
Jul 19, 2021 06:38 pm ET
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round
SEOUL, Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company.
Jul 13, 2021 08:05 am ET
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Jun 22, 2021 08:05 am ET
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment. The Guardant360 TissueNext™ test, the company’s first tissue-based test, is now available, if needed, to help oncologists identify patients with advanced cancer who may benefit
Jun 18, 2021 08:23 pm ET
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
Please replace the release dated April 30, 2021, with the following corrected version due to changes in the fifth paragraph.
Jun 18, 2021 07:57 pm ET
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
Please replace the release dated May 19, 2021 with the following corrected version due to a change in the fourth paragraph.
Jun 08, 2021 08:05 am ET
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company’s new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building and managing pharmaceutical and biotechnology brands through all stages of commercialization, which will be invaluable as the company’s oncology portfolio expands to cover advanced and earlier stage cancers.
Jun 04, 2021 09:10 am ET
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer (CRC) in early-stage cancer patients. This largest ever cohort continues to demonstrate the performance and robustness of the LUNAR-2 assay.1,2
May 28, 2021 01:15 pm ET
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx test as the first and only liquid biopsy companion diagnostic for tumor mutation profiling, or comprehensive genomic profiling, to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor the KRAS G12C mutation and may benefit from LUMAKRAS™ (sotorasib), an FDA-approved KRASG12C inhibitor developed and manufactured by Amgen.
May 28, 2021 01:52 am ET
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of Guardant Health’s new oncology test, Guardant Reveal™.
May 21, 2021 03:14 pm ET
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Muta
Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as the first and only companion diagnostic for Janssen Biotech, Inc.’s (Janssen’s) RYBREVANT™ (amivantamab-vmjw).
May 20, 2021 08:05 am ET
Guardant Health to Participate in Upcoming June Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the following investor conferences.
May 19, 2021 05:56 pm ET
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
Guardant Health, Inc. (Nasdaq: GH), to present data demonstrating the use of the company’s proprietary blood tests to advance precision oncology, including cancer screening, detecting residual or recurrent disease in early-stage cancer, and treatment selection and treatment response monitoring in advanced cancer. Data, from 20 abstracts, will be presented along with other leading medical institutions and pharmaceutical companies, during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-8, 2021.
May 06, 2021 04:05 pm ET
Guardant Health Reports First Quarter 2021 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2021.
May 03, 2021 08:05 am ET
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company’s new Chief Medical Officer (CMO).
Apr 30, 2021 08:05 am ET
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can also be used to evaluate the potential need for adjuvant treatment in post-surgical patients. Until recently, tests developed to detect MRD required tumor tissue to gain the necessary genomic information needed to accurately identify high-risk patients. A new study led by Massachusetts General Hospital Cancer Center and published in Clinical Cancer Re
Apr 29, 2021 08:05 am ET
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference.
Apr 27, 2021 08:05 am ET
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic for Enhertu® (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody-drug conjugate (ADC), being studied in the treatment of patients with advanced metastatic non-small cell lung cancer (NSCLC).
Apr 12, 2021 04:05 pm ET
Guardant Health to Report First Quarter Financial Results on May 6, 2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Apr 10, 2021 08:35 am ET
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company’s proprietary blood tests to advance precision oncology.
Apr 01, 2021 08:05 am ET
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer
Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant Reveal™ liquid biopsy test for the detection and monitoring of minimal residual disease (MRD) in patients with early-stage cancer (stage II and III). Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patient’s status for residual disease, without the need for a tissue biopsy.
Mar 30, 2021 08:05 am ET
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test
Guardant Health, Inc. (Nasdaq: GH) announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Guardant360® CDx test. The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers.
Mar 26, 2021 08:05 am ET
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer
For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often recommended for first-line treatment. A new study in JCO Precision Oncology shows the Guardant360® liquid biopsy test provides an early indication of treatment response to pembrolizumab-based immunotherapy by detecting molecular response or changes in circulating tumor DNA (ctDNA) levels early on.10 The study was led by researchers at the Perelman School of Medicine at the University of Pennsylvania.
Mar 24, 2021 08:05 am ET
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer (CRC) patients. Current medical guidelines call for testing all six biomarkers in advanced CRC before starting treatment,2 yet more than 60 percent of patients are not receiving complete testing which puts them at risk for inappropriate therapy.1
Mar 02, 2021 08:05 am ET
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The test is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib).
Feb 24, 2021 04:05 pm ET
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.
Feb 17, 2021 04:03 pm ET
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences.
Feb 16, 2021 08:05 am ET
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw. The first-of-its-kind commercial test improves the management of early-stage colorectal cancer (CRC) patients by detecting circulating tumor DNA (ctDNA) in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy, and by detecting recurrence months earlier than current standard-of-care methods like carcinoembr
Feb 04, 2021 04:03 pm ET
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will be webcasting a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
Jan 27, 2021 08:05 am ET
Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes
Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung cancer (NSCLC), profiling remains suboptimal due to continued reliance on invasive tissue biopsies for testing. A new study published in JCO Precision Oncology confirms p
Jan 18, 2021 03:00 am ET
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain.
Jan 14, 2021 08:05 am ET
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021.
Dec 30, 2020 04:03 pm ET
Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
Dec 11, 2020 05:00 pm ET
Guardant Health Names Michael Bell as New Chief Financial Officer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its successful transition as a public company.
Dec 07, 2020 08:05 am ET
Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer
The GuardantINFORM platform is an in silico platform that combines de-identified longitudinal clinical information and genomic data collected from our Guardant360 liquid biopsy test. With data from over 135,000 patients, this real-world clinical-genomic dataset of advanced cancer patients is one of the largest in oncology. Notable applications include targeted drug development, clinical trial optimization, and post-marketing studies.
Nov 16, 2020 11:22 pm ET
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering
Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on November 19, 2020, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, th
Nov 16, 2020 06:47 am ET
Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering
Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $150,000,000 principal amount of
Nov 05, 2020 04:03 pm ET
Guardant Health Reports Third Quarter 2020 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020.
Oct 16, 2020 04:05 pm ET
Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Oct 15, 2020 04:05 pm ET
Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers. The initial closing of 7,000,
Oct 07, 2020 09:06 am ET
Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which are being sold by SoftBank Investment Advisers. In addition, SoftBank Investment Advisers has granted the underwriter a 30-day option to purchase up to 700,000
Oct 06, 2020 04:54 pm ET
Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers. In addition, SoftBank Investment Advisers expects to grant the underwriter a 30-day option to purchase up to 700,000 additional shares of common stock at the public offering price, less underwriting discounts
Oct 05, 2020 04:05 pm ET
Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy
Guardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in p
Sep 01, 2020 04:03 pm ET
Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference. Guardant Health’s management is scheduled for a fireside chat on Tuesday, September 15 at 8:45 a.m....
Aug 24, 2020 08:05 am ET
Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test
Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has granted the Guardant-19 test emergency use authorization (EUA) for use in the detection of the novel coronavirus, SARS-CoV-2. The test is being...
Aug 10, 2020 08:05 am ET
Guardant Health to Participate in Upcoming August Investor Conferences
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences. UBS Genomics 2.0 and Medtech Innovations SummitFireside Chat on Tuesday, August 11th at 9 a.m. Pacific Time / 12...
Aug 07, 2020 02:26 pm ET
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant...
Aug 06, 2020 04:03 pm ET
Guardant Health Reports Second Quarter 2020 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter...
Jul 30, 2020 04:10 pm ET
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an...
Jul 21, 2020 08:05 am ET
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the second quarter 2020 after market close on Thursday, August 6, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30...
Jul 08, 2020 08:05 am ET
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Janssen Biotech, Inc. (Janssen) to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an...
Jun 23, 2020 07:55 am ET
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM™  platform featuring an extensive clinical-genomic liquid biopsy...
Jun 22, 2020 09:05 am ET
Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test...
Jun 16, 2020 04:30 pm ET
Guardant Health Appoints Vijaya Gadde to its Board of Directors
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Vijaya Gadde to serve on its Board of Directors. “We’re delighted to welcome Vijaya to our Board of Directors. Vijaya is an outstanding addition to our Board...
Jun 08, 2020 04:03 pm ET
Guardant Health Announces Full Exercise of Option and Closing of Public Offering
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the closing...
Jun 01, 2020 10:32 pm ET
Guardant Health Announces Pricing of Upsized Public Offering
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the pricing...
Jun 01, 2020 04:37 pm ET
Guardant Health Announces Proposed Public Offering of Common Stock
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the...
May 29, 2020 04:03 pm ET
Guardant Health to Participate in the William Blair 2020 Growth Stock Conference
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming William Blair Virtual Growth Stock Conference. Guardant Health’s management is scheduled for a fireside on Thursday, June 11th at 10:00 a.m....
May 15, 2020 08:05 am ET
Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer
Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting the use of the company’s proprietary blood tests to advance precision oncology across the continuum of care at...
May 07, 2020 04:03 pm ET
Guardant Health Reports First Quarter 2020 Financial Results
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter...
May 06, 2020 04:03 pm ET
Guardant Health to Participate in the BofA Securities 2020 Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference. Guardant Health’s management is scheduled for a fireside on Wednesday, May 13th at 1:20 p.m....
May 05, 2020 08:05 am ET
Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer
Guardant Health, Inc. (Nasdaq: GH) has launched the Clear Your View campaign to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced non-small cell lung cancer...
May 02, 2020 10:35 am ET
Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection Program
Guardant Health, Inc. (Nasdaq: GH) presents new data at Digestive Disease Week (DDW) 2020 that highlights the performance of its LUNAR-2 assay and reinforces its potential to improve colorectal cancer (CRC) screening rates by offering a simpler...
Apr 30, 2020 04:03 pm ET
Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the first quarter 2020 after market close on Thursday, May 7, 2020. Company management will be webcasting a corresponding conference call beginning at 2:00 p.m....
Apr 09, 2020 08:05 am ET
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent introduction of alpelisib, a PIK3CA inhibitor. A new study led by Memorial Sloan Kettering Cancer Center and...
Feb 24, 2020 04:03 pm ET
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth...
Feb 12, 2020 06:15 pm ET
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in two upcoming investor conferences. Guardant Health’s management will be presenting at the 9th Annual SVB Leerink Global Healthcare Conference in New York, New...
Feb 10, 2020 04:05 pm ET
Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the fourth quarter and full year 2019 after market close on Monday, February 24, 2020. Company management will host a corresponding conference call beginning at...
Jan 21, 2020 08:30 am ET
Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
Guardant Health, Inc. (Nasdaq: GH) a leading precision oncology company, has appointed Kumud Kalia as the company’s new Chief Information Officer (CIO). Among his responsibilities, he will lead the company’s enterprise applications, information...
Jan 13, 2020 08:30 am ET
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
Guardant Health, Inc. (Nasdaq: GH), announces a  strategic collaboration to develop and help support commercialization of a blood-based companion diagnostic (CDx) test for Amgen’s AMG 510, an investigational oral therapy that inhibits KRAS G12C...
Jan 12, 2020 08:00 pm ET
Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and NRG Oncology, a National Cancer Institute (NCI) funded National Clinical Trials Network group conducting clinical and translational research, have initiated the NRG-GI005...
Dec 30, 2019 04:05 pm ET
Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Guardant Health’s management is...
Dec 19, 2019 01:45 pm ET
Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers
Guardant Health, Inc. (Nasdaq: GH), announced that Palmetto GBA, a Medicare Administrative Contractor for the Molecular Diagnostics (MolDX) program, has expanded local coverage determination (LCD) of the Guardant360® assay, making it the first and...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.